|
ASX - By Stock
|
RAD |
Re:
LinkedIn
|
|
BioInv2025
|
3 |
412 |
1 |
12:26 |
| 12:26 |
ASX - By Stock
|
3
|
412
|
1
|
|
|
ASX - By Stock
|
RAD |
Re:
LinkedIn
|
|
BioInv2025
|
3 |
412 |
2 |
12:20 |
| 12:20 |
ASX - By Stock
|
3
|
412
|
2
|
|
|
ASX - By Stock
|
RAD |
LinkedIn
|
|
BioInv2025
|
3 |
412 |
4 |
11:50 |
| 11:50 |
ASX - By Stock
|
3
|
412
|
4
|
|
|
ASX - By Stock
|
RAD |
Re:
Diamond in the Rough
|
|
BioInv2025
|
2 |
461 |
1 |
16/04/26 |
| 16/04/26 |
ASX - By Stock
|
2
|
461
|
1
|
|
|
ASX - By Stock
|
IMU |
Re:
Ann: 100% and 80% ORRs in Subset Indications in azer-cel study
|
|
BioInv2025
|
132 |
40K |
1 |
15/04/26 |
| 15/04/26 |
ASX - By Stock
|
132
|
40K
|
1
|
|
|
ASX - By Stock
|
ILA |
Re:
ILA - Media coverage
|
|
BioInv2025
|
189 |
60K |
1 |
15/04/26 |
| 15/04/26 |
ASX - By Stock
|
189
|
60K
|
1
|
|
|
ASX - By Stock
|
TLX |
Re:
Telix ASX TLX Breaking News & Current Commentary
|
|
BioInv2025
|
8.4K |
2.9M |
1 |
15/04/26 |
| 15/04/26 |
ASX - By Stock
|
8.4K
|
2.9M
|
1
|
|
|
ASX - By Stock
|
RAD |
Diamond in the Rough
|
|
BioInv2025
|
2 |
461 |
5 |
14/04/26 |
| 14/04/26 |
ASX - By Stock
|
2
|
461
|
5
|
|
|
ASX - By Stock
|
RAD |
Major deal with Regeneron and Telix
|
|
BioInv2025
|
0 |
216 |
1 |
14/04/26 |
| 14/04/26 |
ASX - By Stock
|
0
|
216
|
1
|
|
|
ASX - By Stock
|
RAD |
Re:
RAD101
|
|
BioInv2025
|
1 |
501 |
2 |
11/04/26 |
| 11/04/26 |
ASX - By Stock
|
1
|
501
|
2
|
|
|
ASX - By Stock
|
TLX |
Re:
Industry Analysis
|
|
BioInv2025
|
7 |
3.0K |
1 |
10/04/26 |
| 10/04/26 |
ASX - By Stock
|
7
|
3.0K
|
1
|
|
|
ASX - By Stock
|
TLX |
Re:
Industry Analysis
|
|
BioInv2025
|
7 |
3.0K |
1 |
10/04/26 |
| 10/04/26 |
ASX - By Stock
|
7
|
3.0K
|
1
|
|
|
ASX - By Stock
|
TLX |
Industry Analysis
|
|
BioInv2025
|
7 |
3.0K |
2 |
10/04/26 |
| 10/04/26 |
ASX - By Stock
|
7
|
3.0K
|
2
|
|
|
ASX - By Stock
|
CU6 |
Re:
Industry Analysis
|
|
BioInv2025
|
1 |
983 |
1 |
10/04/26 |
| 10/04/26 |
ASX - By Stock
|
1
|
983
|
1
|
|
|
ASX - By Stock
|
RAD |
RAD101
|
|
BioInv2025
|
1 |
501 |
1 |
09/04/26 |
| 09/04/26 |
ASX - By Stock
|
1
|
501
|
1
|
|
|
ASX - By Stock
|
RAD |
Re:
Ann: RAD202 Phase 1 HEAT Trial Advances to Dose Level 3
|
|
BioInv2025
|
8 |
1.6K |
0 |
09/04/26 |
| 09/04/26 |
ASX - By Stock
|
8
|
1.6K
|
0
|
|
|
ASX - By Stock
|
RAD |
Re:
Ann: RAD202 Phase 1 HEAT Trial Advances to Dose Level 3
|
|
BioInv2025
|
8 |
1.6K |
0 |
09/04/26 |
| 09/04/26 |
ASX - By Stock
|
8
|
1.6K
|
0
|
|
|
ASX - By Stock
|
RAD |
Re:
Ann: RAD202 Phase 1 HEAT Trial Advances to Dose Level 3
|
|
BioInv2025
|
8 |
1.6K |
0 |
09/04/26 |
| 09/04/26 |
ASX - By Stock
|
8
|
1.6K
|
0
|
|
|
ASX - By Stock
|
RAD |
Scaling like a blockbuster
|
|
BioInv2025
|
0 |
234 |
1 |
09/04/26 |
| 09/04/26 |
ASX - By Stock
|
0
|
234
|
1
|
|
|
ASX - By Stock
|
RAD |
Re:
Ann: RAD202 Phase 1 HEAT Trial Advances to Dose Level 3
|
|
BioInv2025
|
8 |
1.6K |
5 |
08/04/26 |
| 08/04/26 |
ASX - By Stock
|
8
|
1.6K
|
5
|
|
|
ASX - By Stock
|
RAD |
Re:
Ann: RAD202 Phase 1 HEAT Trial Advances to Dose Level 3
|
|
BioInv2025
|
8 |
1.6K |
5 |
08/04/26 |
| 08/04/26 |
ASX - By Stock
|
8
|
1.6K
|
5
|
|
|
ASX - By Stock
|
RAD |
Re:
Ann: RAD and Siemens Sign Clinical Supply Agreement for RAD101
|
|
BioInv2025
|
5 |
1.6K |
9 |
07/04/26 |
| 07/04/26 |
ASX - By Stock
|
5
|
1.6K
|
9
|
|
|
ASX - By Stock
|
RAD |
Re:
Novartis just bought early phase 1/2 her2 drug for $2b
|
|
BioInv2025
|
1 |
555 |
2 |
03/04/26 |
| 03/04/26 |
ASX - By Stock
|
1
|
555
|
2
|
|
|
ASX - By Stock
|
RAD |
Novartis just bought early phase 1/2 her2 drug for $2b
|
|
BioInv2025
|
1 |
555 |
1 |
03/04/26 |
| 03/04/26 |
ASX - By Stock
|
1
|
555
|
1
|
|
|
ASX - By Stock
|
RAD |
Re:
Consistent buying (accumulation) on Nasdaq today
|
|
BioInv2025
|
4 |
917 |
0 |
02/04/26 |
| 02/04/26 |
ASX - By Stock
|
4
|
917
|
0
|
|
|
ASX - By Stock
|
RAD |
Re:
Consistent buying (accumulation) on Nasdaq today
|
|
BioInv2025
|
4 |
917 |
0 |
02/04/26 |
| 02/04/26 |
ASX - By Stock
|
4
|
917
|
0
|
|
|
ASX - By Stock
|
RAD |
Re:
Consistent buying (accumulation) on Nasdaq today
|
|
BioInv2025
|
4 |
917 |
1 |
02/04/26 |
| 02/04/26 |
ASX - By Stock
|
4
|
917
|
1
|
|
|
ASX - By Stock
|
RAD |
Re:
Consistent buying (accumulation) on Nasdaq today
|
|
BioInv2025
|
4 |
917 |
1 |
02/04/26 |
| 02/04/26 |
ASX - By Stock
|
4
|
917
|
1
|
|
|
ASX - By Stock
|
RAD |
Consistent buying (accumulation) on Nasdaq today
|
|
BioInv2025
|
4 |
917 |
0 |
02/04/26 |
| 02/04/26 |
ASX - By Stock
|
4
|
917
|
0
|
|
|
ASX - By Stock
|
RAD |
Lantheus per quarterly report looking for tuck-in
|
|
BioInv2025
|
0 |
232 |
4 |
30/03/26 |
| 30/03/26 |
ASX - By Stock
|
0
|
232
|
4
|
|
|
ASX - By Stock
|
RAD |
Re:
RAD 101 Shows 90% Primary End Point Success in Brain Metastases Tria
|
|
BioInv2025
|
1 |
510 |
0 |
28/03/26 |
| 28/03/26 |
ASX - By Stock
|
1
|
510
|
0
|
|
|
ASX - By Stock
|
RAD |
RAD 101 Shows 90% Primary End Point Success in Brain Metastases Tria
|
|
BioInv2025
|
1 |
510 |
0 |
27/03/26 |
| 27/03/26 |
ASX - By Stock
|
1
|
510
|
0
|
|
|
ASX - By Stock
|
RAD |
Re:
Ann: RAD Doses First Patient in RAD 402 Phase 1 Clinical Study
|
|
BioInv2025
|
5 |
1.2K |
8 |
27/03/26 |
| 27/03/26 |
ASX - By Stock
|
5
|
1.2K
|
8
|
|
|
ASX - By Stock
|
RAD |
What ChatGPT thinks Lantheus would pay..
|
|
BioInv2025
|
0 |
229 |
2 |
26/03/26 |
| 26/03/26 |
ASX - By Stock
|
0
|
229
|
2
|
|
|
ASX - By Stock
|
RAD |
Re:
Strong partnering interest for rad101
|
|
BioInv2025
|
13 |
1.9K |
0 |
26/03/26 |
| 26/03/26 |
ASX - By Stock
|
13
|
1.9K
|
0
|
|
|
ASX - By Stock
|
RAD |
Re:
Strong partnering interest for rad101
|
|
BioInv2025
|
13 |
1.9K |
2 |
25/03/26 |
| 25/03/26 |
ASX - By Stock
|
13
|
1.9K
|
2
|
|
|
ASX - By Stock
|
RAD |
Re:
Strong partnering interest for rad101
|
|
BioInv2025
|
13 |
1.9K |
1 |
25/03/26 |
| 25/03/26 |
ASX - By Stock
|
13
|
1.9K
|
1
|
|
|
ASX - By Stock
|
RAD |
Re:
Strong partnering interest for rad101
|
|
BioInv2025
|
13 |
1.9K |
1 |
25/03/26 |
| 25/03/26 |
ASX - By Stock
|
13
|
1.9K
|
1
|
|
|
ASX - By Stock
|
RAD |
Re:
Strong partnering interest for rad101
|
|
BioInv2025
|
13 |
1.9K |
1 |
25/03/26 |
| 25/03/26 |
ASX - By Stock
|
13
|
1.9K
|
1
|
|
|
ASX - By Stock
|
RAD |
Re:
Strong partnering interest for rad101
|
|
BioInv2025
|
13 |
1.9K |
1 |
25/03/26 |
| 25/03/26 |
ASX - By Stock
|
13
|
1.9K
|
1
|
|
|
ASX - By Stock
|
RAD |
Re:
Strong partnering interest for rad101
|
|
BioInv2025
|
13 |
1.9K |
2 |
25/03/26 |
| 25/03/26 |
ASX - By Stock
|
13
|
1.9K
|
2
|
|
|
ASX - By Stock
|
RAD |
Re:
Strong partnering interest for rad101
|
|
BioInv2025
|
13 |
1.9K |
2 |
25/03/26 |
| 25/03/26 |
ASX - By Stock
|
13
|
1.9K
|
2
|
|
|
ASX - By Stock
|
RAD |
Re:
Strong partnering interest for rad101
|
|
BioInv2025
|
13 |
1.9K |
2 |
25/03/26 |
| 25/03/26 |
ASX - By Stock
|
13
|
1.9K
|
2
|
|
|
ASX - By Stock
|
RAD |
Re:
Strong partnering interest for rad101
|
|
BioInv2025
|
13 |
1.9K |
2 |
25/03/26 |
| 25/03/26 |
ASX - By Stock
|
13
|
1.9K
|
2
|
|
|
ASX - By Stock
|
RAD |
Strong partnering interest for rad101
|
|
BioInv2025
|
13 |
1.9K |
2 |
25/03/26 |
| 25/03/26 |
ASX - By Stock
|
13
|
1.9K
|
2
|
|
|
ASX - By Stock
|
RAD |
Re:
Ann: RAD101 2nd interim Ph.2b data - 90% achieve primary endpoint
|
|
BioInv2025
|
12 |
2.9K |
3 |
24/03/26 |
| 24/03/26 |
ASX - By Stock
|
12
|
2.9K
|
3
|
|
|
ASX - By Stock
|
RAD |
Re:
Ann: RAD101 2nd interim Ph.2b data - 90% achieve primary endpoint
|
|
BioInv2025
|
12 |
2.9K |
2 |
24/03/26 |
| 24/03/26 |
ASX - By Stock
|
12
|
2.9K
|
2
|
|
|
ASX - By Stock
|
RAD |
Re:
Ann: RAD101 2nd interim Ph.2b data - 90% achieve primary endpoint
|
|
BioInv2025
|
12 |
2.9K |
2 |
24/03/26 |
| 24/03/26 |
ASX - By Stock
|
12
|
2.9K
|
2
|
|
|
ASX - By Stock
|
RAD |
Re:
Ann: RAD101 2nd interim Ph.2b data - 90% achieve primary endpoint
|
|
BioInv2025
|
12 |
2.9K |
2 |
24/03/26 |
| 24/03/26 |
ASX - By Stock
|
12
|
2.9K
|
2
|
|
|
ASX - By Stock
|
RAD |
Re:
Huge buyer showed up on Friday on nasdaq
|
|
BioInv2025
|
2 |
639 |
2 |
22/03/26 |
| 22/03/26 |
ASX - By Stock
|
2
|
639
|
2
|
|